Skip to main content
. 2022 Aug 26;13:945930. doi: 10.3389/fimmu.2022.945930

Table 8.

The relative effectiveness of booster immunization of COVID-19 vaccines to prevent SARS-CoV-2 infection and COVID-19 caused by the Omicron variant.

Type of disease Type of vaccine No. of studies RR/OR (95% CI) P h/I 2 (%)& VE (%) (95% CI)# P Vaccine name
One dose of COVID-19 vaccine booster immunization*
Omicron variant (B.1.1.529)
Cohort studies: SARS-CoV-2 infection Overall 5 0.386 (0.289, 0.514) <0.001/86.1 61.4 (48.6, 71.1) <0.001
RNA-based vaccine 4 0.372 (0.258, 0.538) <0.001/89.5 62.8 (46.2, 74.2) <0.001 BNT162b2; mRNA-1273
Case–control studies: symptomatic COVID-19 Overall 3 0.326 (0.309, 0.344) 0.205/37.0 67.4 (65.6, 69.1) <0.001 BNT162b2; mRNA-1273
Omicron variant (BA.2)
Cohort studies: symptomatic COVID-19 Overall 2 0.422 (0.244, 0.731) 0.111/60.6 57.8 (26.9, 75.6) 0.002 BNT16b2
Severe COVID-19 Overall 2 0.122 (0.087, 0.173) 0.650/0.0 87.8 (82.7, 91.3) <0.001 BNT16b2
COVID-19-related death Overall 1 0.110 (0.060, 0.186) NA 89.0 (81.4, 94.0) <0.001 BNT16b2
Two doses of COVID-19 vaccine booster immunization to prevent the Omicron variant (B.1.1.529) infection &
Non-randomized clinical studies: SARS-CoV-2 infection Overall 2 0.784 (0.568, 1.081) 0.465/0.0 21.6 (-8.1, 43.2) 0.138 BNT162b2; mRNA-1273
Symptomatic COVID-19 Overall 2 0.621 (0.432, 0.893) 0.607/0.0 37.9 (10.7, 56.8) 0.010 BNT162b2; mRNA-1273
Cohort studies: SARS-CoV-2 infection Overall 3 0.508 (0.482, 0.537) 0.148/47.6 49.2 (46.3, 51.8) <0.001
RNA-based vaccine 2 0.521 (0.468, 0.582) 0.058/72.1 47.9 (41.8, 53.2) <0.001 BNT16b2
Severe COVID-19 Overall 2 0.182 (0.073, 0.459) 0.244/26.3 81.8 (54.1, 92.7) <0.001
COVID-19-related death Overall 1 0.070 (0.010, 0.460) NA 93.0 (54.0, 99.0) <0.001

*Comparison between booster vaccinees and non-booster vaccinees groups; #Vaccine effectiveness = 100*(1–RR) % or 100*(1–OR) %& Comparison between two doses of COVID-19 vaccine booster immunization and one dose of COVID-19 vaccine booster immunization groups, VE, vaccine effectiveness.